Bacterial Extracts as Immunomodulators for the Prevention of Recurrent Respiratory Infections in Children by M. Giovannini et al.
Bacterial Extracts as Immunomodulators for the Prevention of Recurrent
Respiratory Infections in Children
Giovannini M, Salvini F* and Riva E
Pediatric Department University of Milan, San Paolo Hospital – Milan, Italy
*Corresponding author: Filippo Salvini, Pediatric Department University of Milan, San Paolo Hospital, Via Di Rudinì, 820142, Milan-Italy, Tel: +39 02 8184 4666; Fax:
+39 02 8184 3810; E-mail: filippo.salvini@ao-sanpaolo.it
Rec Date: Dec 23, 2013, Acc date: May 30, 2014, Pub date: June 4, 2014
Copyright: © 2014 Giovannini M, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Abstract
Acute respiratory tract infections (ARTI) are the more frequent causes of morbidity and mortality in children. This
review was conducted to assess the existing evidence concerning bacterial extracts efficacy in the prevention of
pediatric ARTI.
The data sources for the identification of clinical trials and reviews included principal bibliographic databases
(MEDLINE, Embase, Cochrane Library, PubMed/www.ncbi.nlm.nih.gov). Selected clinical trials only involved
children suffering from recurrent ARTI.
Bacterial extracts may reduce the incidence of ARTI of about 40% in toddlers (2-5 years), school boys (6-12
years) and children at higher ARTI risk (e.g. children living in orphanages). Among others, the active treatment with
OM-85 led to 26, 2% fewer patients with recurrent ARTI. Data from the literature are encouraging, particularly for
treatment with OM-85.
The strengthening of pre-clinical and clinical research is necessary to allow routine recommendation of bacterial
extracts prescription for ARTI prevention in children.
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Introduction
Acute respiratory tract infections (ARTI: acute nasopharyngitis,
sinusitis, acute otitis, tonsillitis, viral croup, or pneumonia) are
characterized by the onset of more than six respiratory infections per
year or more than one upper respiratory infection per month or more
than three lower respiratory infections during the period of maximum
exposure (September to April), in a child that does not suffer
pathological conditions to justify respiratory infections recurrence,
such as primary immunodeficiencies, HIV infection, cystic fibrosis,
immotile cilia syndrome or congenital abnormalities [1]. In western
countries ARTI occurs in 25% of children within the first year of life
and in 18% of children in the age group of 1-4 years [2].
ARTI are a common problem mainly in pre-school age, due to the
presence of unfavourable environmental conditions, including early
socialization, as well as the immaturity and inexperience of the
immune system.
In particular, immunological immaturity that characterizes the pre-
school years makes this age most exposed to ARTI. Though it is a
benign condition, destined to evolve favorably around 12 years of life,
ARTI represent a health care system, as they interfere with the child's
welfare and lead to important medical-legal costs [2].
It resulted therefore crucial to attend preventive mechanisms in
pre-school age.
In 80% of cases these infections are caused by rhinovirus,
parainfluenza and influenza viruses and the remaining 20% are due to
β-hemolytic streptococcus group A.
The risk factors are mostly environmental, such as early
socialization, passive smoking and pollution exposure; the small
airway caliber and the difficulty to blow the nose or cough up
secretions helps to increase the risk of contracting respiratory
infections in infants and toddlers.
In the child suffering ARTI some alterations in load of one or more
elements of the immune response are detectable. The occurrence of
these changes in the immune response appears to be due to the
negative action that many viruses and some bacterial agents can play
against the lymphocyte and granulocyte function. These changes are,
however, mild and transient, and there seems no immunological
disregulation that can be defined as typical of the child suffering from
ARTI [1].
The immune defects in children with recurrent respiratory
infections have been frequently reported in the literature and include
altered T Lymphocytes helper/suppressor ratio in 50% of cases,
reduced T-lymphocyte response to mitogens such as PHA
(phytohemagglutinin) in 30%, reduced chemotactic and phagocytic
activity of neutrophils in 66-100% of cases and impaired NK cell
function in another 30% [3].
Although falling under physiological conditions, the relapse of
infections is a cause of concern for families and a relevant public
health issue. In addition to the management of the individual episodes,
the major interest is to prevent and positively influence the natural
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history of ARTI. Approaching this kind of patients, it is also necessary
to exclude adverse pathological factors such as allergy, asthma and
adeno-tonsillar hypertrophy.
It should be avoided, at least temporarily, environmental factors,
such as the frequency in child community, which facilitate the onset
and relapse of respiratory infections.
Patients presenting with greater clinical severity could benefit by
some simple diagnostic tests: complete blood count with leucocytes
differential count, immunoglobulin levels, protein electrophoresis (in
order to detect α-1-antitrypsin defect, which is associated with reduced
α-1-globulin levels), sweat testing (recommended in recurrent lower
respiratory tract infections).
Adenoidectomy is recommended for recurrent otitis if adenoidal
hypertrophy is documented. Tonsillectomy can also be indicated in
relapsing tonsillitis.
Anti-pneumococcal [4] and anti-influenza vaccinations [5] also
play an important role in the prevention of ARTI.
Actually, there is increasing interest on the clinical efficacy of
biological immune response modifiers, arguing that these could lead to
a better immune response and therefore better clinical outcome, with
shorter duration of symptoms, reduction in the number of antibiotic
treatments and fewer days lost from kindergarten/school. These
products are expected to correct subtle immune defects observed in
children with ARTI (e.g. deficient chemotaxis of granulocytes,
alterations in lymphocyte subpopulations) [6-9].
The main objective of this review was to examine the effectiveness
of the more studied bacterial extracts available on the market to steer
its use in clinical practice.
The data sources for the identification of trials and reviews included
principal bibliografic databases (MEDLINE, Embase, Cochrane
Library, and PubMed/www.ncbi.nlm.nih.gov).
Results
Between bacterial extracts we can include two major categories:
Compounds that contain killed bacteria or chemical/mechanical
bacterial lysates: OM 85, PMBL
Compounds that contain immunogenic components such as
ribosomes and glycoproteins: D53, RU 41740
Bacterial extracts are specific and non-specific stimulating agents,
indicated in the prevention and treatment of respiratory infections,
particularly in acute and chronic bronchitis, pharyngitis, tonsillitis,
laryngitis, rhinitis, sinusitis and otitis. They can also be used as
adjuvants in case of infections resistant to common antibiotics or in
the treatment of complications [10]. These drugs are able to activate
monocytes and macrophages derived from the presence of structures
of the bacterial wall, such as protidoglicans or lipopolysaccharide,
which interact with the TLR-toll like receptor expressed on the surface
of monocytes. This interaction activates monocytes, their
differentiation into immature dendritic cells and subsequently in
antigen presenting cells. The presentation of antigen on mature
dendritic cells induces T helper function and maturation of B
lymphocytes into plasma cells with subsequent production of
antibodies, including the salivary IgA. Such antibodies opsonize
bacteria, subsequently phagocyted by granulocytes.
Spisek et al. in their study evaluated the effect of different bacterial
immunomodulators on the maturation of immature monocyte-
derived dendritic cells. According to current knowledge about the
activation of dendritic cells by microbial products, it is not surprising
that lysats or bacterial extracts induce in vitro maturation of dendritic
cells, through activation of Toll-like receptor. More surprising is the
fact that several immunomodulators induce this activation unevenly.
The authors speculate that this may in part be explained by differences
in their composition and due to the different production techniques.
The results obtained in this study are relevant to understand the
mechanism of action of in vivo immunomodulatory drugs, up to now
largely unexplained. All these products are administered orally and
come to the intestinal lumen, where they can be delivered to dendritic
cells localized in the mucosa. Their entry into dendritic cells can be
done either via M cells or by a mechanism that uses the tight junctions
between the epithelial cells in the intestinal lumen. The bacterial
uptake then results in activation of dendritic cells migrate to secondary
lymphoid organs and initiation of an immune response [11].
This immunological effect leads to significant reduction in the
number of acute infections and, moreover, in the number and
duration of hospitalizations [6] and, as a direct consequence,
important reduction in health care costs [7]. The results from the
studies conducted to date on bacterial lysates are encouraging.
OM-85 is an immunostimulant extracted from 8 bacterial
pathogens of the upper respiratory tract. It contains standardized
lyophilized fractions per capsule from the following bacteria:
Haemophilus influenzae, Streptococcus pneumoniae, Klebsiella
pneumoniae, Klebsiella ozaenae, Staphylococcus aureus, Streptococcus
pyogenes, Streptococcus viridans, and Neisseria catarrhalis. OM-85
contains 3, 5 mg of standardized lyophilized fractions per capsule from
the 8 bacteria.
OM-85 enhances antimicrobial defenses by eliciting IL-12–
dependent synthesis of IFN-γ by CD4+ T cells [12]. Huber et al. [13]
analyzed the immunomodulatory effects of OM-85 in vitro and in vivo
and have found that in spleen cell supernatants levels of the TH1-
associated cytokine IFN-γ were increased and levels of the TH2-
associated cytokine IL-4 were decreased. The immunoprotective
effects of OM-85 might result from its ability to up regulate the TH1
response.
Bessler et al. administered OM-85 by the oral route to mice, to
stimulate protective mucosal immunity against influenza virus
infection [14]. They distinguished three treatment groups: all animals
in the group treated with 1,75 mg OM-85/mouse has survived,
compared to 70% surviving in the group treated with 0,175 mg/mouse
and the untreated control group; treated animals presented with
milder clinical symptoms in respect to untreated mices. Additionally,
this study suggests that higher dose of OM-85 may have a stimulatory
effect. The group treated with the higher dose of OM-85 also showed a
lower loss of body weight than the other two groups. These data
confirm results from a previous paper published by the same author
suggesting that OM-85 enhances the efficacy of influenza vaccine in
the mice [15].
Several randomized clinical trials have shown that OM-85 can
reduce the number of ARTI of 25-50% in adults and children [16-21].
However, these studies were designed to demonstrate the preventive
effect of OM-85 on AIRT in children with recurrent infections defined
by the presence of diagnostic symptoms for at least 48 hours.
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Steurer-Stey et al. [22] in 2007 used a partially meta-analytical
approach of published data with OM-85. They concluded that their
“sistematic review provides weak evidence that oral
immunostimulation with bacterial extracts prevents acute AIRT in
children”. The 13 studies included in the analyses were considered of
low to moderate quality due to limited size of trials, different
endpoints and difference in- outcomes definition, occultation of
treatment allocation and details about statistical analyses, sponsorship
of pharmaceutical companies and conflict of interest with the authors.
More recently Schaad in 2010 published a systematic review on
efficacy of OM-85 in the prevention of pediatric ARTI. This review
included 22 publications: nine studies were retained as relevant.
During the observation period recurrence of ARTI (defined by 3 or
more ARTI per 6 months) was 32% in patients treated with the OM-85
vs 58, 2% of the placebo treated population, indicating that the active
treatment led to 26, 2% fewer patients with recurrent ARTI; a
significant reduction in the use of antibiotic therapy was also
registered. The NNT was 6.2 considering patients with 1 or more
ARTI in a 6 month period; if considering children with 3 or more
ARTI, the NNT was 3.8 (Table 1) [23].
Author (year) 1 or more ARTI 3 or more ARTI
OM-85 Placebo OM-85 Placebo
Schaad et al. (2002) [24] 103 (85.8%) 87 (87%) 39 (32.5%) 44 (44%)
Gutierrez-Tarango and Berber (2001)
[19]
23 (85.2%) 28 (100%) 14 (51.9%) 23 (82.1%)
Jara-Perez and Berber (2000) [17] 86 (86%) 100 (100%) 14 (14%) 70 (70%)
Del Rio et al. (2003) [25] 2 (10%) 20 (100%) 14 (70%) 19 (95%)
Paupe (1990) [21] 37 (60.7%) 46 (83.6%) 19 (31.1%) 34 (61.8%)
Zagar and Löfler-Badzek (1988) [26] 8 (27.6%) 9 (40.9%) 1 (3.4%) 5 (22.7%)
Schaad et al. (1986) [27] 39 (86.7%) 48 (98%) 28 (62.2%) 28 (57.1%)
Gomez-Barreto et al. (1998) [18] 13 (50%) 21 (70%) 8 (30.8%) 12 (40%)
Pooled
(significance: P<0.001)
311 (72.7%) 359 (88.9%) 137 (32%) 235 (58.2%)
Number needed to treat 6.2 3.8
Odds ratios OM-85: placebo 0.33 (95% CI 0.23, 0.49) 0.33 (95% CI 0.25, 0.45)
"Robust analysis" after deleting Jara-Perez [17] (2000) as positive 'outlier' & Schaad [27] (1986) as negative 'outlier':
Pooled
(significance: P<0.001)
186 (65.7%) 211 (82.7%) 95 (33.6%) 137 (53.7%)
*: Test for heterogeneity: P=0.001 for 1 or more ARTI, P<0.00001 for 3 or more ARTI; †: Test for heterogeneity: P>0.1.
Table 1: Number of patients with ARTI (≥ 1 or ≥ 3 ARTI/6 months), per trial & treatment (Schaad et al. [23])
The mean number of ARTI in the previous year was similar in
patients treated with OM-85 and placebo in most of the studies, but
clinical trials differ in age of treated patients and in therapeutic
regimens.
In addition, the incidence of minor adverse events (mainly
gastrointestinal or cutaneous findings) was 17, 7% for the OM-85
treated group and 18, 2% for those treated with placebo. Serious
adverse events were reported in 1% vs 0.5%, withdrawals due to
adverse event in 1.3% vs 0.7%, respectively. Anyhow, no causal
relationship has been established for any of these adverse events [23].
Razi et al. [28] in 2010 conducted a study which included children
from 1 to 6 years old with 3 or more acute wheezing attacks induced
by respiratory tract illness in the previous 6 months. This study was a
randomized, double-blind, placebo-controlled, parallel-group study
with OM-85 in patients with recurrent wheezing. It was conducted
from August 2007 to September 2008 in a hospital setting in Ankara,
Turkey. The children received 1 capsule of OM-85 or placebo per day
for 10 consecutive days in each of 3 months. Patients were evaluated
monthly and whenever they had respiratory tract symptoms. If
patients had a wheezing attack, the number of days to clinical cure, the
number of days that β2-agonists and oral steroids were used and the
number and duration of hospitalizations were recorded.
They demonstrated that treatment with OM-85 significantly
reduced the incidence of acute virus-provoked wheezing attacks: the
main factor associated with the lowering in wheezing attacks was a
reduction in ARTI. OM-85 significantly reduced the mean incidence
of ARTI and acute nasopharyngitis by 31.5% and 37.9%, respectively.
Moreover, the decrease in the number and duration of wheezing
attacks after administration of OM-85 could have positive secondary
effects, such as reduced use of short-acting β2-agonists or systemic/
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topical corticosteroids, fewer visits to emergency services and lost
work days by parents.
Data from the literature are globally encouraging but more clinical
studies are necessary to allow some routine preventive treatment
recommendation.
PMBL is a polyvalent mechanical bacterial lysate obtained by
mechanical lysis of 48 billion bacteria commonly responsible for upper
and lower respiratory tract infections (S. aureus, S. pyogenes, K.
pneumoniae, S. viridans, K. ozaenae, H. influenzae serotype B, M.
catarrhalis, and S. pneumoniae).
It is produced through a process that preserves the structure of the
bacterial antigens and consists in mechanical lysis, without the use of
any chemical products to denature the antigenic structure of bacteria.
This ensures a preparation having excellent antigenic properties. In in
vitro study, it has been demonstrated that the particulate fraction of
the antigens was more efficient than the soluble antigens in inducing
maturation of the dendritic cells.
A recent publication has shown that PMBL, thanks to its preserved
antigenic structures, is 10-100 times more effective than chemical
lysates to trigger an immune response [29]. This could explain why
bacterial lysates obtained by mechanical lysis are more powerful than
chemical lysates for prophylaxis [29]. Indeed, although OM-85 and
Polyvalent mechanical bacterial lysate (PMBL) are bacterial lysate
made from the same wide range pathogenic bacteria, they are
substantially different: OM-85 is the product of alkaline proteolysis, a
process that may determine protein denaturation, with a consequent
lower immunogenicity of the antigens themselves, whereas PMBL is
produced through mechanical lysis by increasing pressure on bacterial
cell walls, which ensures a preparation having excellent antigenic
properties. This combined with the large variety of pathogens used
and its sublingual mode of administration, confer to PMBL optimal
immunogenic activity [29].
The development of an effective mucosal vaccine has potentially a
number of advantages, including lowering of bacterial carriage levels
in the respiratory tract, decreasing the incidence and severity of
exacerbations, decreasing hospitalization due to exacerbations, and
reducing the need for antibiotics. In particular sublingual
administration guarantees effective protection of the respiratory
mucosae, which represent the first barrier to infection, making it
possible to bypass the gastroenteric tract. This administration has a
downside: the compliance of the patient. In fact, for optimal
administration of PMBL, the preparation must be kept under the
tongue for at least 5-7 minutes. It’s simple to think that this procedure
can be conducted only with children who are old enough (i.e. 5 years)
and sufficiently motivated to understand the need for respecting this
procedure [30].
It is recommended in the prevention of acute, sub-acute, recurrent
or chronic infections of the upper and lower airways in adults and
children [31].
PMBL have already shown efficacy in the prophylaxis of
exacerbations in Chronic Obstructive Pulmonary Disease (COPD), a
state characterized by airflow limitation that is preventable and
treatable, but not fully reversible and usually progressive [32].
The clinical data available in COPD patients indicated a positive
trend in term of reduction of acute exacerbations rate and duration,
beneficial effect on symptoms, reduction in antibiotics use,
hospitalization time and possibility to improve the patient’s quality of
life [8].
The literature supports the possibility that bacterial
immunostimulants might be considered as possible adjuvants in the
prevention of influenza episodes, and prolongs antibody response to
influenza vaccine strains. In fact, some data indicate interesting
synergic effects of bacterial extracts in extending the immunological
response to influenza vaccine in COPD patients [33].
Data obtained in vitro, by using the cytofluorimetry technique, have
proven that PMBL can induce the activation of dendritic cells [34]
and, in general, it can promote the activation of innate immune
response and specific ones both in vitro and in vivo [35].
Moreover, clinical trials [36] clearly demonstrate that this use
decreases the number of respiratory infections. It indicates that the use
of PMBL might be recommended for also preventing influenza
episodes.
A pilot study involving 89 children aged 10 months-10 years
showed that the treatment with PMBL significantly reduced the rate of
recurrent respiratory infections, not only among the same children in
relation to the previous winter, but also in comparison with untreated
children during the same winter (mean number of infective episodes
per patient 7.84 vs 4.78, P ≤ 0.05 with PMBL; 6.78 vs 4.78, P ≤ 0.05
without PMBL); also phlogosis indexes (PCR, plasma mucoprotein
and white blood cell) were significantly lower in the treated group, and
the values of B-lymphocytes were found to be increased (9.9 with
PMBL vs 5.9 without PMBL) [30].
Although the results of several studies are encouraging, it would be
worthwhile to carry out further trials that will be well-designed in term
of blinding and randomization procedures and include a higher
number of patients selected.
Also ribosomal immunotherapeutic agent may prevent ARTI in
children. The product name D53 contains Klebsiella pneumoniae
protidoglicans and ribosomal extracts belonging to 4 different
bacterial species, such as S.pneumoniae, K. pneumoniae, S. pyogenes,
H. influenzae. It stimulates production of specific antibodies against
the four bacterial strains included in the compound and, also,
stimulates non-specific immunity; particularly, it stimulates dendritic
cells and enhances expression of surface molecules involved in the
antigen presentation, induces TLR-2 expression, promotes T-cell
differentiation and regulates the relationship Th1/Th2, induces IgA
production, stimulates pro-inflammatory cytokines and of free
radicals production and, finally, stimulates phagocytosis and NK cell
activity [37].
In 2006 Bousquet and Fiocchi [9] reviewed the literature
concerning clinical evidence of D53 efficacy and found that this
product reduced the number and duration of upper or lower ARTI,
fever episodes, number of antibacterial treatments; a smaller number
of lost school days or parent absenteeism from work was also
registered. The 12 clinical trials on children (n=1215) selected were
analyzed in three categories based on pathology: ENT (ear, nose and
throat) infections, mixted ENT/brocopulmonary infections and acute
otitis media. In all three categories the administrations of ribosomal
immunotherapy was statistically more effective than placebo in
preventing recurrence of infectous episodes (between 27% and 68%
fewer ENT infections, between 32% and 61% fewer ENT/
brocopulmonary infections and between 10% and 53% fewer otitis
media vs placebo).
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Adverse events occurred very rarely and their frequency was fewer
to that reported in placebo groups (1.6% in D53 group’s vs 3.2% in the
placebo groups): mostly, adverse events consisted of fever, cutaneous
rashes and otorhinolaryngologic. In conclusion, this review showed
that ribosomal agent could be effective in preventing ARTI in children
[9].
Also cited in the scientific literature is the molecule RU 41740. It’s a
glycoprotein extracted from Klebsiella pneumoniae that stimulates
immune response in the mucosal associated lymphoid tissue, alveolar
macrophages and dendritic cells activity and phagocytosis and, finally,
enhances B-cell antibody production.
The preventive treatment of mice with RU 41740 leads to a fall of
pro-inflammatory cytokines and an increase of IgG antibodies. Using
a mouse model of experimental infection, Nimier et al. [38]
demonstrated that the number of mice alive after infection of
Klebsiella pneumoniae and E. aerogenes increased by 40 and 30-40%,
respectively, in the RU 41740-treated groups compared to the control
groups. In these experimental conditions no significant protection was
conferred by RU 4I740 on mice infected with the gram-positive specie
S. warneri. However, oral administration of 100 mg/kg RU 41740
resulted in a weak but significant increase in the survival rate of mice
infected by the intracellular gram-positive bacterium L.
monocytogenes: four days after infection, the survival rate was already
increased in when RU 41740 was administered at a lower dose (20 mg/
kg). These results suggest that oral treatment with RU 41740 results
not only in a specific protective effect against gram-negative
Enterobacteriaceae and intracellular gram-positive bacteria [38].
In the literature, there are two clinical trials available, dating 1986
and 1990, conducted in France. In a first double-blind, placebo-
controlled study, 45 children aged 1-13 years with a history of ARTI:
20 children received RU 41740 while 22 patients received placebo for 8
days/month for 3 months. Data analysis did not show a statistically
significant difference between two groups (p=0.09). The drug’s
protective effect was demonstrated by the significant reduction in the
duration of infections (10 days vs 34) and antimicrobial therapy (10
days vs 20) over a six-month period in trested patients. Clinical and
biologic tolerance was very satisfactory [39].
In the second one, Bellon et al. administered the product once a
day, 8 days/month for 3 months to 3008 children with a history of
ARTI, aged 1-16 years. Results were encouraging: 75.3% of the
children had either no infection or only one infection during the 3
months follow-up. Tolerance was good in 98.6% of cases, the
remaining percentage presented mild to minor side-effects.
Although the available results are encouraging, further studies are
necessary to confirm the efficacy of the product.
Conclusion
Data from the literature regarding the use of some
immunostimulants in the prevention of ARTI are encouraging in
terms of disease incidence and duration reduction. This analysis may
help the practitioners in identifying the best candidates for
immunostimulant therapy and the role of this therapy and her positive
effects in the prevention of ARTI.
Overall, bacterial lysates and extracts may reduce the incidence of
ARTI of about 40% in toddlers (2-5 years), school boys (6-12 years)
and children with high incidence ARTI (eg children living in
orphanages) [21]. Differences in the composition of bacterial extracts
and the different technology of their production could explain the
variability in their effectiveness [7]. More attention is allocated to
treatment with OM-85, the main formulation in terms of scientific
evidence. Exploratory analysis indicates that efficacy is more
pronounced in patients at hight risk of recurrent ARTI; the benefit of
OM-85 as compared to placebo was notoriously greater in children
with a history of very frequent ARTI.
Future studies should provide details of the ARTI occurring during
the observation period employing a standardized clinical classification,
because so far both the observation period for the collection of data,
both the recurrence of infectious episodes were set arbitrarily.
Therefore we suggest to start from the definition of ARTI quoted at
the beginning that “are characterized by the onset of more than six
respiratory infections per year or more than one upper respiratory
infection per month or more than three lower respiratory infections
during the period of maximum exposure (September to April), in a
child that does not suffer pathological conditions to justify respiratory
infections recurrence [2].
At the time of this review, we did not find any study regarding
healthy children: the studies presented were designed to demonstrate
the effectiveness of bacterial extracts or synthetic immunomodulators
in reducing episodes of acute respiratory infections in children
suffering from ARTI only.
The strengthening of pre-clinical and clinical research will help
provide new answers and new evidence in order to allow routine
recommendation of bacterial extracts and synthetic
immunomodulators prescription for ARTI prevention in children.
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